MUS81

MUS81 structure-specific endonuclease subunit

Explore in graph →CI-GENE-00015920HGNC:29814 ENSG00000172732 NCBI 80198 CIViC Approved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ATM Loss + BRCA2 Loss + MUS81 Loss + NBN Loss + RAD51B LossRAD51B BRCA2 MUS81 NBN ATM1
Olaparib	Malignant Ovarian Neoplasm	Predictive	D	Supports Sensitivity Response	2	submitted	EID11728 To test for genes associated with PARPi response, a literature review of 79 publications was done, followed by CRISPR-Cas9 cell competition assays in combination with olaparib treatment in six EOC cel… (full text at CIViC) PMID 36307400 · Coelho et al., 2022 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (1)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved1 cohort row · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Sarcoma (UCLA, Cell 2024) sarcoma_ucla_2024	unmapped	Ssm	1	63	1.6%	163

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.